Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Sep 27, 2014; 6(9): 670-676
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Table 1 Baseline patient characteristics n (%)
Variables | Number of patients | |
Gender | Male | 30 (81) |
Female | 7 (19) | |
Age (yr) | > 70 | 19 (51) |
≤ 70 | 18 (49) | |
Child-pugh class | A | 33 (89) |
B | 4 (11) | |
Etiology | HCV | 20 (54) |
HBV | 11 (30) | |
Others | 6 (16) | |
TNM stage | III | 16 (43) |
IVa | 8 (22) | |
IVb | 13 (35) | |
Previous therapies | Yes | 31 (84) |
No | 6 (16) | |
AFP (ng/mL) | > 100 | 20 (54) |
≤ 100 | 17 (46) | |
DCP (mAU/mL)a | > 1000 | 20 (59) |
≤ 1000 | 14 (41) | |
Initial dose of sorafenib (mg/d) | 800 | 21 (57) |
< 800 | 16 (43) | |
Nursing intervention | Yes | 24 (65) |
No | 13 (35) |
Table 2 Sorafenib-related adverse events n (%)
Adverse events | Any Grade | Grade 1 | Grade 2 | Grade 3 |
Anorexia | 29 (78) | 8 (22) | 10 (27) | 11 (30) |
Skin toxicitya | 27 (73) | 6 (16) | 8 (22) | 13 (35) |
Fatigue | 23 (62) | 3 ( 8) | 11 (30) | 9 (24) |
Diarrhea | 20 (54) | 9 (24) | 8 (21) | 3 (8) |
Hypoalbuminemia | 19 (51) | 4 (11) | 14 (38) | 1 (3) |
Weight loss | 17 (46) | 7 (19) | 9 (24) | 1 (3) |
Hyperbilirubinemia | 16 (43) | 10 (27) | 5 (14) | 1 (3) |
Decreased platelet count | 14 (38) | 3 (8) | 9 (24) | 2 (5) |
Hypertension | 13 (35) | 2 (5) | 6 (16) | 5 (14) |
Alopecia | 13 (35) | 5 (14) | 8 (22) | 0 (0) |
Anemia | 9 (24) | 4 (11) | 4 (11) | 1 (3) |
Table 3 Variables associated with overall survival
Variables | Univariate | Multivariate | ||
HR(95%CI) | P value | HR(95%CI) | P value | |
Gender, male (vs female) | 0.384 (0.147-1.005) | 0.051 | ||
Age, ≤ 70 yr (vs > 70 yr) | 0.491 (0.225-1.071) | 0.074 | 0.354 (0.135-0.933) | 0.036 |
Previous therapy yes (vs no) | 0.035 (0.128-0.961) | 0.042 | ||
DCP, ≤ 1000 mAU/mL (vs > 1000 mAU/mL) | 0.416 (0.178-0.974) | 0.043 | ||
Initial dose of sorafenib, 800 mg (vs < 800 mg) | 0.405 (0.185-0.888) | 0.024 | ||
Adverse events > grade 2 | ||||
Anorexia - (vs +) | 0.374 (0.158-0.888) | 0.026 | ||
Skin toxicitya + (vs -) | 0.278 (0.122-0.635) | 0.002 | 0.267 (0.102-0.701) | 0.007 |
Fatigue - (vs +) | 0.404 (0.176-0.924) | 0.032 | ||
Hypoalbuminemia - (vs +) | 0.379 (0.170-0.842) | 0.017 | 0.221 (0.085-0.575) | 0.002 |
Table 4 Variables associated with treatment duration
Variables | Univariate | Multivariate | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Age ≤ 70 yr (vs > 70 yr) | 0.543 (0.257-1.147) | 0.110 | ||
Other etiologies (vs HCV infection) | 0.411 (0.191-0.886) | 0.023 | ||
DCP ≤ 1000 mAU/mL (vs > 1000 mAU/mL) | 0.402 (0.190-0.851) | 0.017 | ||
Nursing intervention yes (vs no) | 0.577 (0.278-1.198) | 0.140 | 0.398 (0.181-0.874) | 0.022 |
Efficacy, disease control (vs PD) | 0.431 (0.206-0.903) | 0.026 | ||
Adverse events > grade 2 + (vs -) | ||||
Skin toxicitya | 0.306 (0.139-0.675) | 0.003 | 0.225 (0.095-0.534) | 0.001 |
Diarrhea | 0.352 (0.156-0.796) | 0.012 | ||
Weight loss | 0.555 (0.254-1.213) | 0.140 | ||
Alopecia | 0.236 (0.081-0.686) | 0.008 |
- Citation: Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676
- URL: https://www.wjgnet.com/1948-5182/full/v6/i9/670.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i9.670